Introduction: Neuropsychiatric Challenges in Neuro-oncology

Managing neuropsychiatric symptoms in patients with primary or metastatic brain tumors presents an exceptionally complex clinical challenge for the multidisciplinary team. Agitation, delirium, and psychosis frequently emerge during the disease course, often as a direct result of tumor progression or as side effects of aggressive treatments like surgery and radiation. These symptoms necessitate the use of antipsychotic medications to ensure patient safety and improve quality of life. However, evaluating the antipsychotic seizure risk in this population requires a nuanced understanding of the altered neurobiology present in neuro-oncology. Brain tumors do not merely occupy space; they fundamentally reshape the cortical environment into a state of chronic hyperexcitability. This transition occurs through various biochemical and structural changes that significantly lower the seizure threshold. While antipsychotics are essential for behavioral management, clinicians must weigh their therapeutic benefits against the potential for provoking seizures. This article explores the intricate relationship between tumor biology and psychotropic liability. By integrating oncology, neurology, and psychiatry, we can better address the behavioral needs of these patients while maintaining neurophysiologic stability and preventing further neurological deterioration.

Mechanisms of Tumor-Associated Cortical Hyperexcitability

The pathophysiology of seizures in brain tumor patients involves a multifaceted disruption of normal neuronal signaling. One primary driver is glutamatergic excess, where the peritumoral environment becomes saturated with excitatory neurotransmitters. Tumors often impair astrocytic glutamate regulation, leading to a failure in clearing these substances from the synaptic cleft. Furthermore, recent research highlights the role of neuroligin-3-mediated signaling, where neuron-glioma synapses actually promote tumor growth and enhance network excitability. In IDH-mutant gliomas, the accumulation of the oncometabolite D-2-hydroxyglutarate further destabilizes cortical circuits by mimicking glutamate structure. Structural factors also play a critical role. Peritumoral edema increases intracranial pressure and disrupts local microcirculation, leading to metabolic instability. Additionally, treatment-related neurotoxicity from radiotherapy and chemotherapy can cause cumulative damage to inhibitory interneurons. When these factors converge, the brain's inherent "brakes" fail, making the cortex highly susceptible to paroxysmal discharges. This baseline instability is the foundation upon which antipsychotic medications act, potentially tipping the balance toward clinical seizures. Therefore, understanding these mechanisms is vital for risk stratification.

Evaluating Antipsychotic Seizure Risk in Neuro-Oncology

Not all antipsychotics share the same level of seizure liability. In general psychiatric populations, second-generation agents typically demonstrate lower risk than older, low-potency compounds. However, these safety profiles change when applied to patients with structural brain disease. Among the medications used, clozapine remains the most concerning due to its dose-dependent reduction of the seizure threshold. Low-potency first-generation antipsychotics, such as chlorpromazine, also carry significant risk. In contrast, risperidone and aripiprazole are generally considered safer options for patients with brain tumors. These agents have shown lower intrinsic pro-convulsant activity in clinical studies. Quetiapine and olanzapine occupy an intermediate risk level, often requiring cautious titration. When clinicians assess the antipsychotic seizure risk, they must also consider the metabolic clearance of these drugs. Many patients in neuro-oncology have altered hepatic or renal function, which can lead to higher systemic concentrations. Therefore, starting with the lowest effective dose and prioritizing agents with better safety profiles is essential. The goal is to control psychiatric symptoms without compromising the patient's neurological status.

The Impact of Antiseizure Medications on Behavior

The management of brain tumor-related epilepsy often involves long-term use of antiseizure medications (ASMs). While these drugs are necessary for preventing seizures, they can paradoxically complicate the psychiatric picture. Levetiracetam, one of the most commonly prescribed ASMs due to its lack of drug-drug interactions, is frequently associated with behavioral dysregulation. Patients may experience increased agitation, anxiety, or even aggression, which then prompts the initiation of antipsychotic therapy. This creates a challenging cycle where the treatment for one condition exacerbates the need for treatment in another. Other ASMs like valproic acid may offer mood-stabilizing benefits but carry risks of hematologic toxicity or hyperammonemia. Consequently, the choice of ASM is a critical clinical modifier. Switching from levetiracetam to agents with better behavioral profiles, such as lacosamide or lamotrigine, might reduce the requirement for antipsychotics. Understanding these interactions allows the multidisciplinary team to optimize the medication regimen. By addressing the root cause of behavioral disturbance, clinicians can minimize the overall burden of psychotropic medications and their associated risks.

Clinical Modifiers and Patient-Specific Vulnerabilities

Several factors influence an individual's susceptibility to seizures when starting an antipsychotic. Tumor location is a primary determinant; lesions in the frontal and temporal lobes are significantly more epileptogenic than those in the infratentorial compartment. These regions are also central to the networks governing behavior and emotion, meaning neuropsychiatric symptoms often localize to the same areas that are prone to seizing. Tumor grade also matters, as low-grade gliomas often have higher seizure rates due to slower growth and more extensive network integration. Furthermore, the timing of treatment is crucial. Patients undergoing active radiotherapy or those in the immediate postoperative period are at their highest level of cortical instability. Metabolic factors, such as hyponatremia or systemic infections, can further lower the seizure threshold. Clinicians must also account for polypharmacy, which is rampant in neuro-oncology. Steroids like dexamethasone can cause psychiatric symptoms while simultaneously altering the metabolism of other drugs. Therefore, a comprehensive risk assessment must account for the dynamic state of the patient's tumor biology and their overall treatment trajectory.

A Seizure-Informed Framework for Prescribing

To improve patient safety, we propose an interdisciplinary framework for managing antipsychotic use in neuro-oncology. This seizure-informed approach begins with a thorough evaluation of the psychiatric indication and the current seizure status. If a patient is at high risk, clinicians should prioritize non-pharmacological interventions or behavioral-modifying ASMs first. When an antipsychotic is necessary, the selection should favor high-potency second-generation agents like aripiprazole or risperidone. Dosing should follow a "start low, go slow" principle, with frequent monitoring of both behavioral response and seizure activity. Collaboration between psychiatrists, neurologists, and oncologists is the cornerstone of this framework. Regular medication reviews can help identify opportunities to de-escalate treatment or switch to safer alternatives as the patient's clinical state evolves. Furthermore, educating caregivers about the signs of both seizures and side effects ensures earlier detection of complications. By integrating tumor biology and pharmacodynamics into clinical decision-making, we can provide more personalized and safer care. This holistic perspective ensures that behavioral management does not come at the expense of neurological integrity.

Frequently Asked Questions

Which antipsychotics are considered highest risk for seizures in brain tumor patients?

Clozapine and low-potency first-generation antipsychotics, such as chlorpromazine, confer the greatest seizure risk. These medications significantly lower the seizure threshold in a dose-dependent manner. In patients with structural brain disease like tumors, their pro-convulsant effects are amplified, making them generally unfavorable unless other therapeutic options have been completely exhausted.

How does levetiracetam complicate psychiatric management in neuro-oncology?

Levetiracetam is often linked to behavioral side effects including irritability, agitation, and mood instability. These symptoms may necessitate the introduction of antipsychotic medications. Consequently, clinicians should consider if the patient's psychiatric symptoms are drug-induced before adding new agents, potentially switching the antiseizure medication to one with fewer behavioral risks.

Why are IDH-mutant gliomas particularly associated with increased seizure activity?

IDH-mutant gliomas produce the oncometabolite D-2-hydroxyglutarate (D-2HG), which is structurally similar to glutamate. D-2HG acts as an excitatory stimulus on neuronal receptors, promoting cortical hyperexcitability. This biochemical disruption, combined with tumor-driven network changes, creates a highly unstable environment that increases the likelihood of seizures when antipsychotics are introduced.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Taj F et al. Antipsychotics and Seizure Risk in Patients with Brain Tumors: Mechanisms, Modifiers, and Clinical Insights. Curr Psychiatry Rep. 2026 Jul 13. doi: 10.1007/s11920-026-01696-y. PMID: 42440017.

Alberta Health Services. Seizure Management in Adult Patients with Primary and Metastatic Brain Tumours. Clinical Practice Guideline. 2023.

Sirven JI, Wingerchuk DM, Drazkowski JF, et al. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc. 2004;79(12):1489-1494.

Maschio M, Sperati F, Dinapoli L, et al. Seizures in brain tumors: pathogenesis, risk factors and management. Int J Mol Med. 2025;55:82.